Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ANAB | Healthcare | $46.25 | 499.64K | $1.43B | 7.27 | ― | Strong Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ANAB | AnaptysBio | 46.25 | 23.71 | 105.16% |
| Name | Price | % Change | |
|---|---|---|---|
| ANAB | $46.25 | +105.16% |
Reports Q1 revenue $30.274M, consensus $33.46M. “Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in
AnaptysBio (ANAB) is scheduled to report 3rd quarter earnings on 11/10/2026. Regarding Q3 estimates, Wall Street analysts expect AnaptysBio to post earnings of -$1.84 per share. Revenue expectations are pegged
AnaptysBio (ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK (GSK) company, and Quimilza with Vanda, announced that GSK has received U.S. Food and
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on AnaptysBio, with a price target of $95.00. Joseph Pantginis has given his Buy rating due
JPMorgan lowered the firm’s price target on AnaptysBio (ANAB) to $60 from $70 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first on
Leerink lowered the firm’s price target on AnaptysBio (ANAB) to $81 from $90 and keeps an Outperform rating on the shares. The firm notes the company reported June quarter results
The major averages started the week sharply higher, with the rise in AI-related stocks driving the tech-dominant Nasdaq Composite to record high on a 2.3% surge. Within the benchmark S&P
Reports Q2 revenue $27.5M, consensus $20.12M. Cash, cash equivalents and investments totaled $164.1M as of June 30, compared to $211.6M as of December 31, 2025, for a decrease of $47.5M
AnaptysBio (ANAB) is scheduled to report 2nd quarter earnings on 09/11/2026. Regarding Q2 estimates, Wall Street analysts expect AnaptysBio to post earnings of -$0.47 per share. Revenue expectations are pegged
TD Cowen lowered the firm’s price target on AnaptysBio (ANAB) to $70 from $75 and keeps a Buy rating on the shares. The firm updated its model after GSK (GSK)
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| ANAB | buy | Reiterated | Nov 13, 2026 | |||
| ANAB | buy | Reiterated | Nov 13, 2026 | |||
| ANAB | buy | Reiterated | Nov 13, 2026 | |||
| ANAB | buy | Reiterated | Oct 21, 2026 | |||
| ANAB | buy | Assigned | Sep 30, 2026 | |||
| ANAB | buy | Assigned | Sep 22, 2026 | |||
| ANAB | buy | Assigned | Aug 25, 2026 | |||
| ANAB | buy | Reiterated | Mar 31, 2026 | |||
| ANAB | buy | Reiterated | Mar 4, 2026 | |||
| ANAB | buy | Reiterated | Dec 16, 2025 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
